2021. Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s53. DOI:https://doi.org/10.25251/skin.5.supp.53.